1241P Safety monitoring of adjuvant 2 weekly durvalumab for patients with stage III NSCLC: Implications for a 4 weekly regimen during the COVID-19 pandemic and beyond

https://doi.org/10.1016/j.annonc.2020.08.114Get rights and content
Under an Elsevier user license
open archive

Cited by (0)